A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone Combo With Humalog Mix25 and With Simultaneous Injections of Humalog and Lantus in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Insulin glargine/insulin lispro (Primary) ; Insulin glargine; Insulin lispro; Insulin neutral protamine lispro/insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Adocia
- 16 Sep 2016 Results assessing pharmacodynamic profile of BioChaperone Combo, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 08 Sep 2016 According to an Adocia media release, data from this trial were presented at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 2016.
- 06 Jun 2016 Data will be presented at the American Diabetes Association 76th Scientific Sessions 2016, according to an Adocia media release.